Amgen Inc. (AMGN) — Research Snapshot as of 2026-11-02

Not investment advice. Below is a point-in-time research summary based on the sources provided. All figures reflect the reporting as stated in each source; where sources conflict, the discrepancy is noted.

1. Recent Catalysts (last ~1–3 months)

DeLLphi-305 clinical readout (IMDELLTRA/tarlatamab + IMFINZI/durvalumab) — Oct 24, 2026 Amgen announced that adding IMDELLTRA to IMFINZI reduced the hazard of death by 58% versus IMFINZI alone in a Phase 3 trial for extensive-stage small-cell lung cancer (ES-SCLC) that had not progressed after initial durvalumab and chemotherapy. Reported figures included a median survival of 21.1 months vs. 12.7 months, and ~80% vs. 53% one-year survival. Amgen described these as interim outcomes, not guaranteed patient benefits, and the catalyst concerns an earlier treatment setting rather than a new approval. [1]